Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTB-04
- Development stage
- Preclinical
- Lead developer
- Next Innovative Therapeutics
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
PTB-04 is a nutraceutical candidate developed by Next Innovative Therapeutics (Nintx) for the treatment of Irritable Bowel Syndrome (IBS). Derived from Brazilian biodiversity, PTB-04 is designed to target biological pathways involved in gastrointestinal health, potentially modulating the gut microbiome to alleviate symptoms of IBS. Next Innovative Therapeutics has completed clinical development for this nutraceutical program.
Beyond the preview
Go deeper on PTB-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTB-04.